Catherine E. Muehlenbein

829 total citations
31 papers, 599 citations indexed

About

Catherine E. Muehlenbein is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, Catherine E. Muehlenbein has authored 31 papers receiving a total of 599 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 5 papers in Genetics. Recurrent topics in Catherine E. Muehlenbein's work include Lung Cancer Treatments and Mutations (21 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Lung Cancer Diagnosis and Treatment (8 papers). Catherine E. Muehlenbein is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Lung Cancer Diagnosis and Treatment (8 papers). Catherine E. Muehlenbein collaborates with scholars based in United States, Australia and United Kingdom. Catherine E. Muehlenbein's co-authors include Crystal Pike, Howard G. Birnbaum, Ronald B. Natale, Gerhardt Pohl, Eugene D. Shapiro, Marietta Vázquez, Matthew Cartter, Edward B. Hayes, S.M. Babineaux and Astra M. Liepa and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Catherine E. Muehlenbein

27 papers receiving 589 citations

Peers

Countries citing papers authored by Catherine E. Muehlenbein

Since Specialization

Citations

This map shows the geographic impact of Catherine E. Muehlenbein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine E. Muehlenbein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine E. Muehlenbein more than expected).

Fields of papers citing papers by Catherine E. Muehlenbein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine E. Muehlenbein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine E. Muehlenbein. The network helps show where Catherine E. Muehlenbein may publish in the future.

Co-authorship network of co-authors of Catherine E. Muehlenbein

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine E. Muehlenbein. A scholar is included among the top collaborators of Catherine E. Muehlenbein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine E. Muehlenbein. Catherine E. Muehlenbein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Knowledge, skills, and confidence gaps impacting treatment decision making in relapsed/refractory chronic lymphocytic leukemia and mantle cell lymphoma: a quantitative survey study in France, Germany, and the United States 2024 ·BMC Cancer ·(unknown), Florence Cymbalista, Martin Dreyling, Nirav N. Shah, Suzanne Murray, R. Del Fiacco, Catherine E. Muehlenbein, (unknown)	0
2	CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Catherine E. Muehlenbein, Catherine C. Coombs, Nirav N. Shah, Wojciech Jurczak, Jennifer A. Woyach, Chan Y. Cheah, Krish Patel, Kami J. Maddocks, Yucai Wang, (unknown), Sarang Abhyankar, Donald E. Tsai, Toby A. Eyre	1
3	Long‐term safety with ≥12 months of pirtobrutinib in relapsed/refractory B‐cell malignancies 2023 ·Hematological Oncology ·(unknown), Catherine C. Coombs, Nirav N. Shah, Wojciech Jurczak, Jennifer A. Woyach, Chan Y. Cheah, Krish Patel, Kami J. Maddocks, Catherine E. Muehlenbein, Chu Wang, (unknown), Donald E. Tsai, Toby A. Eyre	1
4	A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer 2023 ·Journal of Comparative Effectiveness Research ·(unknown), (unknown), Katherine B. Winfree, Catherine E. Muehlenbein, (unknown), Vanita Tongbram, Howard Thom	3
5	Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001 2022 ·Journal of Thoracic Oncology ·Caroline E. McCoach, Christian Rolfo, Alexander Drilon, Mario E. Lacouture, Benjamin Besse, Kōichi Goto, Viola W. Zhu, Daniel S.W. Tan, (unknown), Laura A. Potter, Jennifer Kherani, Victoria Soldatenkova, Elizabeth Olek, Catherine E. Muehlenbein, Keunchil Park	27
6	Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189 2021 ·Lung Cancer ·Edward B. Garon, Joachim G.J.V. Aerts, (unknown), Catherine E. Muehlenbein, Patrick Peterson, Maria Teresa Rizzo, Shirish M. Gadgeel	10
7	NU01.01 Real World Data on Maintenance Therapy Utilization and Overall Survival Among Advanced Non-Small Cell Lung Cancer Patients Treated with Pemetrexed in combination with Pembrolizumab and Platinum Chemotherapy in the US 2021 ·Journal of Thoracic Oncology ·(unknown), (unknown), Yimei Han, Catherine E. Muehlenbein, Yajun Emily Zhu, (unknown)	2
8	KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis 2020 ·Cancer Treatment and Research Communications ·Rebecca Goulding, (unknown), Gebra Cuyún Carter, Mark E. Boye, Kristin M. Sheffield, William J. John, (unknown), Catherine E. Muehlenbein, Li Li, Min‐Hua Jen, (unknown), Jeroen J. Jansen, Eric Druyts	49
9	Real-world safety of pemetrexed, carboplatin, and pembrolizumab in U.S. NSCLC patients. 2020 ·Journal of Clinical Oncology ·Catherine E. Muehlenbein, Sangmi Kim, (unknown), Ana B. Oton, (unknown), (unknown), (unknown)	2
10	PCN131 COST EFFECTIVENESS OF PEMETREXED IN COMBINATION WITH PEMBROLIZUMAB AND PLATINUM CHEMOTHERAPY (PEM+PEMBRO+PLAT), FOR INITIAL TREATMENT OF PATIENTS WITH METASTATIC NON-SQUAMOUS (NSQ) NON-SMALL CELL LUNG CANCER (NSCLC) IN THE U.S. 2019 ·Value in Health ·(unknown), Catherine E. Muehlenbein, (unknown), Katherine B. Winfree, (unknown), Y. Zhu, Sinem Perk, (unknown)	1
11	PCN91 COST-EFFECTIVENESS OF IMMUNOTHERAPY-BASED DRUG REGIMENS FOR THE INITIAL TREATMENT OF PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER 2019 ·Value in Health ·(unknown), (unknown), Catherine E. Muehlenbein, Katherine B. Winfree, Y. Zhu, Theresa Baker	1
12	Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis 2018 ·Advances in Therapy ·Kathleen M. Aguilar, Katherine B. Winfree, Catherine E. Muehlenbein, Yajun Emily Zhu, Thomas W. Wilson, (unknown), Eric Nadler	11
13	Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy 2018 ·Patient ·(unknown), Lisa M. Hess, Edward S. Kim, Benjamin Levy, Mohamed Mohamed, David Waterhouse, Antoinette J. Wozniak, Sarah Goring, Kerstin Müller, Catherine E. Muehlenbein, (unknown), Yajun Emily Zhu, Ana B. Oton, Jennifer L. Ersek, Katherine B. Winfree	26
14	An exploratory subgroup analysis of race and gender in squamous cancer of the head and neck: Inferior outcomes for African American males in the LORHAN database 2014 ·Oral Oncology ·D. Neil Hayes, Guangbin Peng, Eduardo J. Pennella, Anwar Hossain, Gebra Cuyún Carter, Catherine E. Muehlenbein, Coleman K. Obasaju	14
15	Healthcare Costs and Workloss Burden of Patients with Chemotherapy-Associated Peripheral Neuropathy in Breast, Ovarian, Head and Neck, and Nonsmall Cell Lung Cancer 2012 ·PubMed ·Crystal Pike, Howard G. Birnbaum, Catherine E. Muehlenbein, Gerhardt Pohl, Ronald B. Natale	159
16	Evaluation of the Reliability of Electronic Medical Record Data in Identifying Comorbid Conditions among Patients with Advanced Non-Small Cell Lung Cancer 2011 ·SHILAP Revista de lepidopterología ·Catherine E. Muehlenbein, J. Russell Hoverman, Stephen K. Gruschkus, (unknown), Clara Chen, (unknown), (unknown), (unknown), Gerhardt Pohl	6
17	Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer 2010 ·Journal of Thoracic Oncology ·Robert W. Klein, (unknown), Catherine E. Muehlenbein, Astra M. Liepa, S.M. Babineaux, (unknown), Lee S. Schwartzberg	58
18	Neutropenia-Related Costs in Patients Treated with First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer 2009 ·Journal of Managed Care Pharmacy ·Michael E. Stokes, Catherine E. Muehlenbein, Martin Marciniak, Douglas E. Faries, (unknown), Theresa Gillespie, Joseph Lipscomb, Kevin Knopf, Don P. Buesching	47
19	Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer 2009 ·Journal of Thoracic Oncology ·Robert W. Klein, Catherine E. Muehlenbein, Astra M. Liepa, S.M. Babineaux, (unknown), Lee S. Schwartzberg	25
20	Methodological issues in design and analysis of a matched case–control study of a vaccine's effectiveness 2007 ·Journal of Clinical Epidemiology ·Linda M. Niccolai, Lorraine G. Ogden, Catherine E. Muehlenbein, James Dziura, Marietta Vázquez, Eugene D. Shapiro	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact